Tempest Therapeutics Inc
NASDAQ:TPST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Tempest Therapeutics Inc
NASDAQ:TPST
|
US |
|
Metalpha Technology Holding Ltd
NASDAQ:MATH
|
HK |
Intrinsic Value
The intrinsic value of Tempest Therapeutics Inc (TPST) under the Base Case is 0.99 USD per share.
Compared with the current market price of 0.624 USD, the stock appears
Undervalued by 37% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Tempest Therapeutics Does
Tempest Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its main work is to discover and test small-molecule drugs that are designed to change how tumors grow, survive, and interact with the immune system. The company does not sell a broad line of products; its business is built around advancing a small number of drug candidates through clinical trials.
- Headquarters
- United States of America US
- Employees
- 4
- IPO date
- Oct 4, 2012
Revenue & Expenses Breakdown
Tempest Therapeutics Inc
Earnings Waterfall
Tempest Therapeutics Inc
The intrinsic value for Tempest Therapeutics Inc (TPST) under the Base Case is 0.99 USD.
Compared with the current market price of 0.624 USD, the stock appears Undervalued by 37% .